Literature DB >> 27672137

Personalised medicine for multiple sclerosis care.

Arie Gafson1, Matt J Craner2, Paul M Matthews3.   

Abstract

Treatments with a range of efficacy and risk of adverse events have become available for the management of multiple sclerosis (MS). However, now the heterogeneity of clinical expression and responses to treatment pose major challenges to improving patient care. Selecting and managing the drug best balancing benefit and risk demands a new focus on the individual patient. Personalised medicine for MS is based on improving the precision of diagnosis for each patient in order to capture prognosis and provide an evidence-based framework for predicting treatment response and personalising patient monitoring. It involves development of predictive models involving the integration of clinical and biological data with an understanding of the impact of disease on the lives of individual patients. Here, we provide a brief, selective review of challenges to personalisation of the management of MS and suggest an agenda for stakeholder engagement and research to address them.

Entities:  

Keywords:  Treatment response; multiple sclerosis; outcome measurement

Mesh:

Year:  2016        PMID: 27672137     DOI: 10.1177/1352458516672017

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  17 in total

1.  Outcomes after fingolimod to alemtuzumab treatment shift in relapsing-remitting MS patients: a multicentre cohort study.

Authors:  Jessica Frau; Francesco Saccà; Alessio Signori; Damiano Baroncini; Giuseppe Fenu; Pietro Annovazzi; Marco Capobianco; Elisabetta Signoriello; Alice Laroni; Sara La Gioia; Arianna Sartori; Giorgia Teresa Maniscalco; Simona Bonavita; Marinella Clerico; Cinzia Valeria Russo; Antonio Gallo; Caterina Lapucci; Antonio Carotenuto; Maria Pia Sormani; Eleonora Cocco
Journal:  J Neurol       Date:  2019-06-17       Impact factor: 4.849

2.  Effectiveness and baseline factors associated to fingolimod response in a real-world study on multiple sclerosis patients.

Authors:  F Esposito; L Ferrè; F Clarelli; M A Rocca; G Sferruzza; L Storelli; M Radaelli; F Sangalli; L Moiola; B Colombo; F Martinelli Boneschi; G Comi; M Filippi; V Martinelli
Journal:  J Neurol       Date:  2018-02-12       Impact factor: 4.849

3.  Individualized analysis of skin thermosensory thresholds and sensitivity in heat-sensitive people with multiple sclerosis.

Authors:  Davide Filingeri; Georgia Chaseling; Aikaterini Christogianni; Kaltrina Feka; Antonino Bianco; Scott L Davis; Ollie Jay
Journal:  Temperature (Austin)       Date:  2020-05-24

Review 4.  Serum-Based Biomarkers in Neurodegeneration and Multiple Sclerosis.

Authors:  Patrizia LoPresti
Journal:  Biomedicines       Date:  2022-05-06

5.  Immunotherapy for people with clinically isolated syndrome or relapsing-remitting multiple sclerosis: treatment response by demographic, clinical, and biomarker subgroups (PROMISE)-a systematic review protocol.

Authors:  Thomas Lehnert; Christian Röver; Sascha Köpke; Jordi Rio; Declan Chard; Andrea V Fittipaldo; Tim Friede; Christoph Heesen; Anne C Rahn
Journal:  Syst Rev       Date:  2022-07-01

6.  Using a multidimensional unfolding approach to assess multiple sclerosis patient preferences for disease-modifying therapy: a pilot study.

Authors:  Angel Perez Sempere; Vanesa Vera-Lopez; Juana Gimenez-Martinez; Elena Ruiz-Beato; Jesús Cuervo; Jorge Maurino
Journal:  Patient Prefer Adherence       Date:  2017-05-29       Impact factor: 2.711

7.  Commentary on the ECTRIMS-EAN guideline for pharmacological treatment of multiple sclerosis.

Authors:  Alan J Thompson
Journal:  Ther Adv Neurol Disord       Date:  2018-04-17       Impact factor: 6.570

8.  Cytotoxic CD4+ T Cells Drive Multiple Sclerosis Progression.

Authors:  Liesbet M Peeters; Marjan Vanheusden; Veerle Somers; Bart Van Wijmeersch; Piet Stinissen; Bieke Broux; Niels Hellings
Journal:  Front Immunol       Date:  2017-09-20       Impact factor: 7.561

9.  Psychometric properties of the SDM-Q-9 questionnaire for shared decision-making in multiple sclerosis: item response theory modelling and confirmatory factor analysis.

Authors:  Javier Ballesteros; Ester Moral; Luis Brieva; Elena Ruiz-Beato; Daniel Prefasi; Jorge Maurino
Journal:  Health Qual Life Outcomes       Date:  2017-04-22       Impact factor: 3.186

10.  Lipoprotein markers associated with disability from multiple sclerosis.

Authors:  A R Gafson; T Thorne; C I J McKechnie; B Jimenez; R Nicholas; P M Matthews
Journal:  Sci Rep       Date:  2018-11-19       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.